X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
female (4) 4
male (4) 4
adult (3) 3
double-blind method (3) 3
index medicus (3) 3
middle aged (3) 3
psychiatry (3) 3
atypical antipsychotic (2) 2
clinical neurology (2) 2
dose-response relationship, drug (2) 2
isoxazoles - adverse effects (2) 2
isoxazoles - blood (2) 2
long-acting injectable (2) 2
paliperidone palmitate (2) 2
palmitates - adverse effects (2) 2
palmitates - blood (2) 2
pharmacology & pharmacy (2) 2
psp (2) 2
risperidone (2) 2
scale (2) 2
schizophrenia (2) 2
schizophrenia - drug therapy (2) 2
statistics, nonparametric (2) 2
treatment outcome (2) 2
1452-1485 (1) 1
1564-1616 (1) 1
6-week (1) 1
80 and over (1) 1
abridged index medicus (1) 1
acute disease (1) 1
adverse effects (1) 1
aged (1) 1
aged, 80 and over (1) 1
alleles (1) 1
alzheimer disease (1) 1
alzheimer disease - cerebrospinal fluid (1) 1
alzheimer disease - drug therapy (1) 1
alzheimer disease - genetics (1) 1
alzheimer's disease (1) 1
alzheimers disease (1) 1
amyloid beta-peptides (1) 1
amyloid beta-peptides - analysis (1) 1
amyloid beta-peptides - antagonists & inhibitors (1) 1
amyloid beta-peptides - cerebrospinal fluid (1) 1
analysis (1) 1
antagonists & inhibitors (1) 1
antibodies (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antipsychotic agents - adverse effects (1) 1
antipsychotic agents - blood (1) 1
antipsychotic agents - pharmacology (1) 1
antipsychotic agents - therapeutic use (1) 1
apolipoprotein e (1) 1
apolipoproteins e (1) 1
apolipoproteins e - genetics (1) 1
area under curve (1) 1
article (1) 1
biological markers (1) 1
biomarkers - analysis (1) 1
biomarkers - cerebrospinal fluid (1) 1
brain (1) 1
brain - pathology (1) 1
cerebrospinal fluid (1) 1
chemically induced (1) 1
clinical trials (1) 1
clinical trials as topic - methods (1) 1
cognition (1) 1
cognition - drug effects (1) 1
cognitive ability (1) 1
correspondence (1) 1
deltoid (1) 1
dementia disorders (1) 1
disability (1) 1
dizziness - chemically induced (1) 1
drama (1) 1
drug effects (1) 1
drug therapy (1) 1
early works to 1800 (1) 1
edema (1) 1
edema - chemically induced (1) 1
english drama (1) 1
epitope (1) 1
extended-release tablets (1) 1
genetics (1) 1
great britain (1) 1
great britain -- history -- richard iii, 1483-1485 -- drama (1) 1
great britain drama. history richard iii, 1483-1485 (1) 1
great britain history (1) 1
great britain history richard iii, 1483-1485 (1) 1
health aspects (1) 1
health personnel - education (1) 1
historical drama (1) 1
historical drama. gsafd (1) 1
history (1) 1
humanized (1) 1
iii (1) 1
imaging abnormalities (1) 1
immunotherapy (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 4, pp. 322 - 333
In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes.... 
ANTIBODIES | MEDICINE, GENERAL & INTERNAL | EPITOPE | IMAGING ABNORMALITIES | PEPTIDE | MOUSE MODEL | Phosphorylation | Humans | Middle Aged | Male | Positron-Emission Tomography | Treatment Failure | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Female | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Biomarkers - analysis | Alzheimer Disease - drug therapy | tau Proteins - cerebrospinal fluid | Alzheimer Disease - cerebrospinal fluid | Cognition - drug effects | Neuropsychological Tests | Amyloid beta-Peptides - antagonists & inhibitors | Apolipoproteins E - genetics | Intention to Treat Analysis | Amyloid beta-Peptides - analysis | Brain - pathology | Aged | Biomarkers - cerebrospinal fluid | Edema - chemically induced | Alzheimer Disease - genetics | Monoclonal antibodies | Product development | Research | Drug therapy | Alzheimer's disease | Health aspects | Edema | Nuclear magnetic resonance--NMR | Intravenous administration | Neurodegenerative diseases | Cognitive ability | Clinical trials | Cerebrospinal fluid | Patients | Studies | Tau protein | Apolipoprotein E | Immunotherapy | Alleles | Dementia disorders | Alzheimers disease | Brain | Neurosciences | pathology | Biological Markers | Antibodies | Cognition | tau Proteins | 80 and over | genetics | Amyloid beta-Peptides | Apolipoproteins E | Monoclonal | Neurovetenskaper | drug therapy | chemically induced | Humanized | drug effects | Alzheimer Disease | analysis | antagonists & inhibitors | cerebrospinal fluid | adverse effects | therapeutic use
Journal Article
International journal of pharmaceutical compounding, ISSN 1092-4221, 07/2018, Volume 22, Issue 4, pp. 326 - 328
The stability of extemporaneously prepared sodium benzoate oral suspension in cherry syrup and Ora-Sweet was studied. Oral solutions of 250-mg/mL sodium... 
Journal Article